News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Hidehito Horinouchi: Oral – Lung / Thoracic Cancer 1
Hidehito Horinouchi/X
Mar 4, 2025, 09:25

Hidehito Horinouchi: Oral – Lung / Thoracic Cancer 1

Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:

“Oral: Lung / Thoracic Cancer 1
Chairs: Drs. Makoto Nishio, Nobuyuki Yamamoto.

1st Line ICI in KRASm.
Resistance to Alectinib.
MARIPOSA trial.
Zonbertinib / Beamion Lung-1.
Firmonertinib / Read FURTHER.”

Hidehito Horinouchi: Oral - Lung / Thoracic Cancer 1

cancer Hidehito Horinouchi JSMO 2025 Makoto Nishio MARIPOSA trial Nobuyuki Yamamoto OncoDaily Oncology
Special Coverage
Voices
Aug 9, 2025, 15:31
No Two Practices are the Same, and Neither are Their Approaches to Immunotherapy - NCODA
Stories
Aug 9, 2025, 15:19
1,000 Lives, One Message: Never Stop Caring - The Max Foundation
Voices
Aug 9, 2025, 15:05
Al-Ola Abdallah: Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types
Voices
Aug 9, 2025, 14:56
Are You Passionate About Patient Involvement in Cancer Research? - EORTC
Voices
Aug 9, 2025, 14:53
Aravind Palraj: Immune-Related Adverse Events Can Mimic Cancer Flare
Voices
Aug 9, 2025, 14:51
4 Days to Go Until the NSW Cancer Summit 2025 - Cancer Institute NSW
Societies
Aug 9, 2025, 13:59
AACR Project GENIE 18.0: Genomic Insights from 7,900+ Sarcoma and Bone Cancer Patients
Voices
Aug 9, 2025, 13:48
Nicola Normanno joins "From Policy to Practice" - EAPM
Oncolibrary
Aug 9, 2025, 12:50
FDA Grants Accelerated Approval to Zongertinib for HER2 TKD Mutated Non-Squamous NSCLC
Science
Aug 9, 2025, 12:08
Amol Akhade: Zongertinib - A New Targeted Therapy Option for a Rare Molecular Subset of Lung Cancer
Science
Aug 9, 2025, 12:07
UCLA Study Finds: Mailed At-Home Kits Boost Colorectal Cancer Screening for Ages 45–49
Voices
Aug 9, 2025, 11:59
Al-Ola Abdallah: MRD Negativity Isn’t the Finish Line